Tier 2 — strong

Treatment of interstitial cystitis with a quercetin supplement

F Katske, D A Shoskes, M Sender, R Poliakin, K Gagliano, J Rajfer
Techniques in urology 2001 7(1):44

Bibliography

PubMed
PMID 11272677
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignOpen-label uncontrolled interstitial-cystitis pilot
ModelHuman intervention research
Sample22 enrolled patients; 20 completed
InterventionCysta-Q complex providing quercetin 500 mg twice daily
Duration4 weeks
EndpointsSymptoms and quality of life

What the study showed, in plain terms

Published in 2001, this source examined prostate and urinary health. Design: Open-label uncontrolled interstitial-cystitis pilot. Sample/model: 22 enrolled patients; 20 completed. The exposure or intervention was Cysta-Q complex providing quercetin 500 mg twice daily. Follow-up or treatment period: 4 weeks.

Symptoms, problem scores, and global pain ratings improved from baseline.

No placebo control and a multi-ingredient branded preparation. Regression to the mean, expectations, and other ingredients cannot be separated from quercetin effects.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Prostatitis and Chronic Pelvic Pain. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Symptoms, problem scores, and global pain ratings improved from baseline.
  • The recorded outcome domains were Symptoms and quality of life.
  • The result applies to the tested exposure: Cysta-Q complex providing quercetin 500 mg twice daily; 4 weeks.

What this study can and cannot tell us

  • No placebo control and a multi-ingredient branded preparation. Regression to the mean, expectations, and other ingredients cannot be separated from quercetin effects.
  • Without a sufficiently blinded concurrent control, time effects, expectations, co-interventions and regression toward the mean can explain part of an apparent improvement.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Oral Preparation of Hyaluronic Acid, Chondroitin Sulfate, Curcumin, and Quercetin (Ialuril® Soft Gels) for the Prevention of LUTS after Intravesical Chemotherapy
Celeste Manfredi et al. · Pathophysiology : the official journal of the International Society for Pathophysiology · 2022
Tier 2
Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial
D A Shoskes et al. · Urology · 1999

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology